

1. A method of treating a cancer in a patient in need thereof comprising administering *in vivo* a therapeutically effective amount of a composition comprising:

(ii) a pharmaceutical carrier.

3. The method of Claim 2, wherein said viral vector is an adenoviral vector.

5. The method of Claim 1, wherein said cancer is renal cell carcinoma.

6. The method of Claim 1, wherein said expression vector is encapsulated in a liposome.

7. The method of Claim 1, wherein said patient is human.

8. The method of Claim 1, wherein said composition comprises 10^{10} expression vectors per ml.

9. The method of claim 1, wherein said composition further comprises an immunotherapeutic agent, genetic therapeutic, cytokine, prodrug converting enzyme or anticancer agent.

10. The method of claim 1, wherein said composition further comprises a second expression vector comprising a gene

11. The method of claim 1, wherein said expression vector further comprises a second gene encoding an immunotherapeutic agent, genetic therapeutic, cytokine or prodrug converting enzyme;

12. A method of treating restenosis in a patient in need thereof comprising administering *in vivo* a therapeutically effective amount of a composition comprising:

(ii) a pharmaceutical carrier.

(i) an expression vector comprising a gene encoding p21 fused to a gene encoding a prodrug converting enzyme.

15. The method of claim 14, wherein said composition further comprises a pharmaceutically acceptable carrier.

Sept 27